Navigation Links
Ion Torrent Cancer Panel Finds Mutations in One Day
Date:10/12/2011

CARLSBAD, Calif., Oct. 12, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the launch of the Ion AmpliSeq™ Cancer Panel, enabling scientists to sequence dozens of genes in cancer research samples using a simple workflow. Mutations are confirmed within just one day, starting with a single-tube reaction and 10 ng of DNA extracted from fixed, frozen or fresh tissue. Novel Ion AmpliSeq™ kits prepare targeted regions for sequencing in 3.5 hours of total time, with under 10 minutes of hands-on time, just like standard PCR. The method is scalable to hundreds of genes. Current methods require weeks of work to generate hundreds of gene regions via PCR or hybridization-based capture.

This dramatic improvement in time-to-result will accelerate cancer research, enabling even small labs to run thousands of research samples a year.  The Ion AmpliSeq™ Cancer Panel sequences 46 cancer-related genes for over 700 known cancer mutations.  The panel was chosen in collaboration with leading oncologists and cancer researchers. View a video with an Ion AmpliSeq™ user.

Speed: The Ion AmpliSeq™ Cancer Panel enables researchers to sequence 190 amplicons in one day starting with a 3.5 hour amplification reaction, then Ion OneTouch™ template preparation, and finally a sequencing run that takes just 90 minutes.

Simplicity: The Ion AmpliSeq™ Cancer Panel is the simplest solution because researchers just add DNA to a single tube containing all primers. It's as easy to perform as endpoint PCR, so any trained laboratory technician can d
'/>"/>

SOURCE Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ion Torrent Ships New RNA Sequencing Application as Fast, Easy, Affordable Alternative to Microarrays
2. Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe
3. Ignorance is Not Bliss: PSA Test Saves Mens Lives from Prostate Cancer
4. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
5. Genesis Biopharma Signs Worldwide License Agreement with the NIH for Adoptive Cell Therapy to Treat a Variety of Cancers
6. NJ Docs Say Cancer Detection Tool Saves Lives
7. Cancer Patients Can Benefit From Early Detection Of Heart Damage Using Echocardiography
8. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
9. New Research Shows PET Imaging Effective in Predicting Lung Cancer Outcomes
10. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
11. In Honor of National Breast Cancer Awareness Month, Alma Lasers Launches Nationwide Radiation Tattoo Removal Program, Declare Your Freedom
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... a manufacturer of ergonomically designed laboratory equipment for research, ... Japan to sell and service the Hitachi brand ... utilize its network of sales professionals throughout the United ... assistance in application use, product benefits and features, options and accessories, ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a privately ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of January 15, ... at New York Medical College. Oligomerix, which ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Eisai Corporation of North America today announced that the ... review the company,s supplemental new drug application (sNDA) for ... injection) to treat patients with myelodysplastic syndromes (MDS). ... diseases that limit the production of functional blood cells. ...
... Amgen (Nasdaq: AMGN ) today announced that ... Zometa(R) (zoledronic acid) in the treatment of bone metastases ... primary and secondary endpoints and demonstrated superior efficacy compared ... the time to the first on-study Skeletal Related Events ...
Cached Medicine Technology:FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS) 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:4/23/2014)... a country as wealthy as the United States, it may ... not have access to adequate food due to lack of ... , Recent research at the University of Illinois using data ... that the seniors who are dealing with hunger are also ... 8.35 percent of Americans over age 60 faced the threat ...
(Date:4/23/2014)... PROVIDENCE, R.I. Parents and physicians concerned about an ... medical marijuana can breathe a sigh of relief. According ... compared 20 years worth of data from states with ... not lead to increased use among adolescents. The study ... Journal of Adolescent Health . , "Any ...
(Date:4/23/2014)... depletion of self-control, according to research published in ... Psychological Science. , Self-control can be difficult sticking ... a boring textbook are hard things to do. Considerable ... self-control for a long period seems to "deplete" our ... "It is as if self-control is a limited resource ...
(Date:4/22/2014)... a popular high school sport in the United States ... by researchers in the Center for Injury Research and ... compare and describe the occurrence and distribution patterns of ... school athletic training setting among adolescents and teens. , ... Athletic Training , examined data relating to adolescents 13-19 ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:ADHD drug may help preserve our self-control resources 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... Pa., June 1 Practice-Reps, LLC ( http://www.practice-reps.com ) ... to specialty medical practices along the East Coast. The ... a 16-year veteran of the practice marketing industry, to ... experienced marketing support on a part-time basis. , ...
... SAN FRANCISCO, Calif., June 1 Rigel Pharmaceuticals, Inc. ... oral Syk inhibitor, R788, is being evaluated in a ... the National Cancer Institute (NCI), part of the U.S. ... trial will include patients with advanced colorectal, thyroid, non-small ...
... , Collaboration Delivers Cost and Quality Benefits for Widespread ... June 1 SAFC(R) ( www.safcglobal.com ), a member ... and Cherokee Pharmaceuticals(TM) ( www.cherokee-pharma.com ... business, today announced an exclusive strategic partnership that encompasses ...
... , New Product Names for Recently Introduced MicroRNA-based Diagnostics ... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic ... platform yesterday at the American Society of Clinical Oncology ... a presentation entitled "Profiling of Receptor Tyrosine Kinases (RTK) ...
... the mouth and periodontists to ask questions about heart health ... leading killer of men and women in the United States, ... each day. Periodontal disease, a chronic inflammatory disease that destroys ... 75 percent of Americans and is the major cause of ...
... program aimed at reducing criminal behavior in juvenile justice teens ... reducing the teens, rate of pregnancy, according to a new ... in the Department of Psychology at Oregon State University, and ... Learning Center, conducted the research, which will be published in ...
Cached Medicine News:Health News:Practice-Reps Brings Sales and Marketing to the Business of Medical Practice Management 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 3Health News:SAFC(R) & Cherokee Pharmaceuticals(TM) Pool Expertise and Resources With Strategic Partnership For U.S. Market 2Health News:SAFC(R) & Cherokee Pharmaceuticals(TM) Pool Expertise and Resources With Strategic Partnership For U.S. Market 3Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 2Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 2Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 4Health News:Intervention reduces delinquent teenage pregancy rates 2Health News:Intervention reduces delinquent teenage pregancy rates 3
Three-spring evacuator kits with silicone drains, 10 in. hole pattern, trocar and Y-connector tubing...
Reliavac® 400cc kits with silicone round drain with 10 in. hole pattern, trocar, and Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used in the peritoneal cavity to remove large volumes of thick exudate....
Medicine Products: